Cargando…

非小细胞肺癌T790M基因突变研究进展

Patients with advanced non-small cell lung cancer (NSCLC) carrying epidermal growth factor receptor (EGFR) activating mutations benefit from EGFR-tyrosine kinase inhibitor (TKI) treatment, however, most of TKI-treated patients eventually suffer drug resistant after 10-month treatments. Previous stud...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 中国肺癌杂志编辑部 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6000573/
https://www.ncbi.nlm.nih.gov/pubmed/23769347
http://dx.doi.org/10.3779/j.issn.1009-3419.2013.06.08
_version_ 1783331773639294976
collection PubMed
description Patients with advanced non-small cell lung cancer (NSCLC) carrying epidermal growth factor receptor (EGFR) activating mutations benefit from EGFR-tyrosine kinase inhibitor (TKI) treatment, however, most of TKI-treated patients eventually suffer drug resistant after 10-month treatments. Previous studies demonstrated that T790M mutation in exon 20 of EGFR gene would be the essential factor leading to EGFR-TKI resistance, leaving the mechanisms of which elucidative. Current research identified that T790M is an independent, favorable prognostic factor for predicting survival, but whether it is also a predictive biomarker for EGFR-TKI efficacy is still controversial. Up to date, techniques to detect T790M mutation in lung cancer have been greatly improved and the new therapeutic strategies emerged as well. In this review, we summarized the newly updated data about T790M mutation in terms of its mechanisms involved in EGFR-TKI resistant, clinical value, advanced detection assays and ongoing strategies against the mutation subtype.
format Online
Article
Text
id pubmed-6000573
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher 中国肺癌杂志编辑部
record_format MEDLINE/PubMed
spelling pubmed-60005732018-07-06 非小细胞肺癌T790M基因突变研究进展 Zhongguo Fei Ai Za Zhi 综述 Patients with advanced non-small cell lung cancer (NSCLC) carrying epidermal growth factor receptor (EGFR) activating mutations benefit from EGFR-tyrosine kinase inhibitor (TKI) treatment, however, most of TKI-treated patients eventually suffer drug resistant after 10-month treatments. Previous studies demonstrated that T790M mutation in exon 20 of EGFR gene would be the essential factor leading to EGFR-TKI resistance, leaving the mechanisms of which elucidative. Current research identified that T790M is an independent, favorable prognostic factor for predicting survival, but whether it is also a predictive biomarker for EGFR-TKI efficacy is still controversial. Up to date, techniques to detect T790M mutation in lung cancer have been greatly improved and the new therapeutic strategies emerged as well. In this review, we summarized the newly updated data about T790M mutation in terms of its mechanisms involved in EGFR-TKI resistant, clinical value, advanced detection assays and ongoing strategies against the mutation subtype. 中国肺癌杂志编辑部 2013-06-20 /pmc/articles/PMC6000573/ /pubmed/23769347 http://dx.doi.org/10.3779/j.issn.1009-3419.2013.06.08 Text en 版权所有©《中国肺癌杂志》编辑部2013 https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 3.0) License. See: https://creativecommons.org/licenses/by/3.0/
spellingShingle 综述
非小细胞肺癌T790M基因突变研究进展
title 非小细胞肺癌T790M基因突变研究进展
title_full 非小细胞肺癌T790M基因突变研究进展
title_fullStr 非小细胞肺癌T790M基因突变研究进展
title_full_unstemmed 非小细胞肺癌T790M基因突变研究进展
title_short 非小细胞肺癌T790M基因突变研究进展
title_sort 非小细胞肺癌t790m基因突变研究进展
topic 综述
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6000573/
https://www.ncbi.nlm.nih.gov/pubmed/23769347
http://dx.doi.org/10.3779/j.issn.1009-3419.2013.06.08
work_keys_str_mv AT fēixiǎoxìbāofèiáit790mjīyīntūbiànyánjiūjìnzhǎn